Studying how minocycline may affect blood pressure in resistant hypertension
Tests minocycline against placebo in adults with hypertension that resists standard treatment.
Plain-language title generated from the registry record
Registry title: Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Key facts
- Where
- Gainesville, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06246396, who can take part
Where in United States
- UF Clinical Research Center (UF CRC) - CTSIGainesville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Florida
- Trial code
- NCT06246396
- Record updated
- 13 October 2026
- Original description
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:Read full original descriptionShow less
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:
* To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?
Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Inclusion: Age ≥18 years; Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic; The participant agrees to have all study procedures performed.
Exclusion: Recent (≤3 months prior), ongoing, or expected use of oral antibiotics; History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months; Evidence of alcoholism or drug abuse; Known hypersensitivity or contraindication to minocycline or other tetracyclines; Known secondary hypertension; History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year; History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes of standing) in the past year; Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS); Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation; Current pregnancy or anticipated pregnancy during the study.